Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Launched by INSTITUT DE RECHERCHES INTERNATIONALES SERVIER · Aug 1, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with a specific type of brain tumor called astrocytoma, which is caused by a genetic mutation known as IDH-1. The trial is testing a combination of two medications: Vorasidenib and Pembrolizumab. Vorasidenib is designed to target the cancer cells, while Pembrolizumab helps the immune system fight the cancer. The goal is to see how effective this combination is for patients whose tumors have returned or worsened after previous treatments.

To participate in this trial, eligible patients must be between the ages of 65 and 74, have a certain level of physical ability (measured by the Karnofsky Performance Status), and have a confirmed diagnosis of Grade 2 or Grade 3 astrocytoma. It’s important that they have a specific gene mutation and measurable tumor growth as seen on MRI scans. Participants can expect to receive the study drugs and regular monitoring to assess their health and the effects of the treatment. It’s also important to note that this trial is currently recruiting, so there are opportunities for those who meet the criteria to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Have Karnofsky Performance Status (KPS) of ≥ 70%.
• • 2. Have expected survival of ≥ 3 months.
• • 3. Have histologically confirmed Grade 2 or Grade 3 glioma (per the 2016 or 2021 World Health Organization \[WHO\] Classification of Tumors of the central nervous system)
• 4. Have:
• • 1. Documented IDH1-R132H gene mutation; and
• • 2. For Astrocytomas: Absence of 1p19q co-deletion (i.e., exclusion of combined whole-arm deletions of 1p and 19q) and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing. For Oligodendrogliomas: Presence of 1p19q co-deletion (i.e., combined whole-arm deletions of 1p and 19q) by local testing.
• • 5. Have measurable, magnetic resonance imaging (MRI)-evaluable, unequivocal contrast enhancing disease as determined by institutional radiologist/Investigator at Screening on either 2D T1 post-contrast weighted images or 3D T1 post-contrast weighted images. Per mRANO criteria, measurable lesion is defined as at least 1 enhancing lesion measuring ≥ 1 cm x ≥ 1 cm. OR (in the absence of measurable enhancing disease) measurable, MRI-evaluable, unequivocal non enhancing disease as determined by institutional radiologist/Investigator at Screening on either 2D or 3D T2-weighted image or FLAIR. Per RANO 2.0 criteria, measurable lesion is defined as at least 1 non enhancing lesion measuring ≥ 1 cm × ≥ 1 cm.
• • 6. Have recurrent or progressive disease and received prior treatment with chemotherapy, radiation, or both.
• • 7. Surgical resection is indicated for treatment, but surgery is not urgently indicated (e.g., for whom surgery within the next 6-9 weeks is appropriate). (NOTE: This criterion only applies to participants enrolled in the perioperative phase of the study. Participants in the Safety Lead-In should not require surgery).
• Exclusion Criteria:
• • 1. Have received prior systemic anti-cancer therapy within 1 month of the first dose of IMP, radiation within 12 months of the first dose of IMP, or an investigational agent \< 14 days prior to the first dose of IMP. In addition, the first dose of IMP should not occur before a period of ≥ 5 half-lives of the investigational agent has elapsed.
• • 2. Have received 2 or more courses of radiation.
• • 3. Have received any prior treatment with an isocitrate dehydrogenase (IDH) inhibitor; anti-programmed cell death 1 (PD1), anti-programmed cell death ligand 1 (PD-L1), or anti-PD-ligand 2 (L2) agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137); any other checkpoint inhibitor; bevacizumab; or any prior vaccine therapy.
• • Note: Other inclusion and exclusion criteria may apply.